TAYLOR FURBAY: Open Payments
NPI 1134718984 · BEACHWOOD, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$814 in 37 payments from 17 companies in 2025. Trend: 2023 $1,762 · 2024 $1,972 · 2025 $814
Food & beverage: $814
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 1 | $187 |
| ABBVIE INC. | 12 | $178 |
| PFIZER INC. | 4 | $87 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $52 |
| Novo Nordisk Inc | 3 | $48 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $41 |
| Pulmonx Corporation | 1 | $30 |
| Merck Sharp & Dohme LLC | 2 | $30 |
| Gilead Sciences, Inc. | 1 | $22 |
| Corcept Therapeutics | 1 | $22 |
Products named: FARXIGA, VRAYLAR, NURTEC ODT, QULIPTA, JARDIANCE, XIFAXAN, Ozempic, CHARTIS CATHETER.
Industry payments across OH — which companies pay providers there.
